BPC-157 TB-500 is the Wolverine blend: what the literature on each peptide actually shows.

Two peptides sprayed under one name

BPC-157 TB-500 is the research-community name for a two-peptide pairing, tagged on gym forums and supplier sites as the "Wolverine" blend. It is not a single chemical entity, not an approved drug, and not a thing any controlled trial has ever tested as a unit. It is two distinct synthetic peptides put in one vial.

The first is BPC-157 — Body Protection Compound 157, a 15-amino-acid pentadecapeptide (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, MW ~1419.5 Da) derived from a protein found in human gastric juice. In preclinical models it works locally: it up-regulates VEGFR2 and drives downstream Akt-eNOS angiogenic and cytoprotective signaling ^[2]. The second is TB-500 — a synthetic N-acetylated heptapeptide (Ac-LKKTETQ, MW ~889.0 Da) corresponding to the actin-binding region (residues 17-23) of Thymosin Beta-4 ^[5]. It works on the cytoskeleton, sequestering monomeric actin to regulate the cell migration that underlies repair ^[3].

The "synergy" claim rests on those two mechanisms being complementary and largely non-overlapping. That is a reasonable extrapolation. It is also exactly that — an extrapolation. No peer-reviewed study defines a synergy ratio, dose, or endpoint for the two given together ^[6]. This site reads the evidence one constituent at a time, marks every blend-level gap, and keeps the FDA 503A access status in plain sight. For the regulatory picture, start with the Wolverine legal status and FDA 503A category.

What the Wolverine peptide blend is

What is the Wolverine peptide blend?

It is a research-community name for a two-peptide pairing of BPC-157 (a cytoprotective, angiogenic pentadecapeptide) with TB-500 (the synthetic Ac-LKKTETQ actin-binding fragment of Thymosin Beta-4), discussed as a tissue-repair "stack." It is not a single chemical entity and not an approved product. Commercial vials commonly pair the two at a combined mass — for example 10 mg + 10 mg — but no standardized composition or ratio is clinically validated.

What is BPC-157 and TB-500?

BPC-157 is a synthetic 15-amino-acid pentadecapeptide derived from a human gastric-juice protein. TB-500 is a synthetic N-acetylated heptapeptide (Ac-LKKTETQ) corresponding to the actin-binding region of Thymosin Beta-4 ^[5]. The blend pairs the two for their complementary proposed tissue-repair mechanisms — a local angiogenic signal and a cytoskeletal migration signal.

What is the difference between BPC-157 and TB-500?

BPC-157 is a 15-amino-acid gastric-juice-derived peptide acting via VEGFR2/eNOS angiogenesis and growth-hormone-receptor sensitization ^[2]. TB-500 is a 7-amino-acid actin-binding fragment of Thymosin Beta-4 acting via G-actin sequestration and cell migration ^[3]. Different sequences, different sizes, different proposed mechanisms — paired, not merged.

What is the 'Wolverine stack'?

"Wolverine stack" is the research-community term for the BPC-157 + TB-500 pairing. It is a forum and supplier label, not an approved product or a single validated formulation. The name is also conflated with the X-Men character, which is why the cleaner search signal for the pairing is "BPC-157 TB-500."

BPC-157 and TB-500: How the Two Peptides Are Paired

BPC-157 and TB-500 are paired on a two-mechanism rationale. BPC-157 supplies the local signal: VEGFR2 up-regulation feeding an Akt-eNOS angiogenic and cytoprotective cascade, plus growth-hormone-receptor sensitization in tendon fibroblasts ^[2]. TB-500 supplies the cytoskeletal signal: its LKKTETQ helix binds monomeric G-actin 1:1, regulating the actin dynamics that drive cell migration and re-epithelialization ^[3].

Those are described as parallel routes to the same end — better-perfused, faster-migrating, more rapidly resurfaced tissue. On paper they slot together cleanly, which is the whole appeal of the pairing.

The honest caveat sits directly under the rationale: no controlled combination study has defined a synergy ratio, dose, or endpoint for the two peptides given together. The 2025 HSS Journal systematic review of BPC-157 — 36 studies, only one in humans — makes no mention of TB-500 or combination use at all ^[6]. Every "synergy" statement about the Wolverine blend is therefore an extrapolation from two separately characterized mechanisms, not a finding from a study of the blend.

There is a second gap stacked on the first. Most efficacy data attributed to "TB-500" were generated with full-length Thymosin Beta-4 (~4963 Da), not the Ac-LKKTETQ 7-mer that is actually sold ^[4]. The blend leans on full-length-protein data for one of its two components — a caveat the pairing inherits and rarely states. See the research literature on BPC-157 and TB-500 for the mechanism evidence in full.

How this wall is organized

This is an editorial research digest, not a clinic and not a storefront. It indexes what the published literature on each constituent of the Wolverine blend establishes — and, just as deliberately, what it does not.

The evidence pages read one peptide at a time. The research literature on BPC-157 and TB-500 covers the mechanisms and the foundational studies. BPC-157 TB-500 benefits in recovery research collects the tendon, ligament, muscle, and wound-repair findings — all preclinical, all single-compound. BPC-157 TB-500 dosage in the research literature frames the species-and-route context without offering a human protocol, because none is validated.

The access pages keep the regulatory record first. The Wolverine legal status and FDA 503A category states the present-tense FDA position, with citations. The common questions about the Wolverine blend answer the 25 most-asked questions directly, and the cited studies and references list every source with its DOI or PubMed link. Nothing here is medical or legal advice.